Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Comment by SanFrancisco99on Mar 26, 2015 12:00pm

137 Views

Post# 23564490

RE:RE:RE:RE:RE:Blogs, Video, News Releases, Analyst

Hi JKJ:

Thank you. I think those two analysis have been around for a long while. I don't think they have written anything for a long while, but I really don't know for sure so don't take my word on it. Maybe they have something new out there now.

.... but they were listed as analysts in the somewhat distant past.

Bullboard Posts

Mullen Group's Robust Case for Value, Part 1: Less-than-Truckload